Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

被引：32
|
作者：
Speer, Michael E. [1 ]
Fernandes, Caraciolo J. [1 ]
Boron, Marnie [2 ]
Groothuis, Jessie R. [2 ]
机构：
[1] Baylor Coll Med, Dept Pediat, Sect Neonatol, Houston, TX 77030 USA
[2] Medimmune Inc, Gaithersburg, MD 20878 USA
来源：
PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2008年 / 27卷 / 06期
关键词：
cystic fibrosis; RSV; palivizumab; hospitalization;
D O I：
10.1097/INF.0b013e3181673c15
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The Palivizumab Outcomes Registry collected data on 19,548 high-risk infants who received >= 1 dose of palivizumab and followed prospectively from 2000 through 2004. Ninety-one children with cystic fibrosis (CF) were identified who received palivizumab off label. None of the infants with CF who received prophylaxis was hospitalized as a result of respiratory syncytial virus lower respiratory tract infection. Evaluations of palivizumab use in infants with CF could be warranted.
引用
收藏
页码：559 / 561
页数：3
相关论文
共 50 条
  • [41] Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
    Parikh, Rohan C.
    McLaurin, Kimmie K.
    Margulis, Andrea V.
    Mauskopf, Josephine
    Ambrose, Christopher S.
    Pavilack, Melissa
    Candrilli, Sean D.
    INFECTIOUS DISEASES AND THERAPY, 2017, 6 (04) : 477 - 486
  • [42] Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection
    Robinson, RF
    Nahata, MC
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (03) : 259 - 264
  • [43] Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
    O'Hagan, Shaun
    Galway, Niamh
    Shields, Michael D.
    Mallett, Peter
    Groves, Helen E.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 103 - 112
  • [44] Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
    Resch, Bernhard
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (09) : 2138 - 2149
  • [45] Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab
    Wang, Daniel Y.
    Saleem, Mahwesh
    Paes, Bosco A.
    Mitchell, Ian
    Li, Abby
    Lanctot, Krista L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2019, 38 (08) : 775 - 780
  • [46] Motavizumab for the prevention of respiratory syncytial virus infection in infants
    Gill, Michelle A.
    Welliver, Robert C., Sr.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (10) : 1335 - 1345
  • [47] Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis
    Ginsberg, Gary M.
    Somekh, Eli
    Schlesinger, Yechiel
    ISRAEL JOURNAL OF HEALTH POLICY RESEARCH, 2018, 7
  • [48] A review of cost-effectiveness of palivizumab for respiratory syncytial virus
    Hussman, Julia M.
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 553 - 567
  • [49] Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
    Gary M. Ginsberg
    Eli Somekh
    Yechiel Schlesinger
    Israel Journal of Health Policy Research, 7
  • [50] Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
    Ordonez, Jaime E.
    Huertas, Victor M.
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
12345